Impact of the treatment of chronic myeloid leukaemia by tyrosine-kinase inhibitors on sick leaves refund: a nationwide cohort study.

Cécile ConteFlora VayrMarie-Christelle PajiepFabien DespasFrançoise HuguetMaryse Lapeyre MestreMartin GauthierFabrice Herin

Published in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2022)

More than 25% of working-age CML patients had at least one sick leave within 2 years of TKI initiation, with a higher impact of second generation TKI, and with a median duration of 115 days.

Keyphrases

chronic myeloid leukemia
end stage renal disease
tyrosine kinase
ejection fraction
newly diagnosed
chronic kidney disease
advanced non small cell lung cancer
bone marrow
dendritic cells
acute myeloid leukemia
patient reported